UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combination that halts the growth of cancer cells that carry HER2 mutations. Patients with cancers harboring HER2 mutations eventually develop resistance to a promising new cancer drug currently clinical trial.
Published in journal Cancer Cell, the researchers found that another drug, already on the market, counters that resistance and blocks the cancer, thereby providing the basis for a novel drug combination against cancers mutations in the HER2 gene.
The team led by Dhivya Sudhan, PhD, with the Harold C. Simmons Comprehensive Cancer Center and collaborators evaluated data from a molecularly guided trial where patients with tumors with HER2 mutations were treated with the HER2 inhibitor neratinib.
Patients’ cancers were sequenced as the disease progressed during treatment. While analyzing the study data, Sudhan discovered that an effective way to offset eventual resistance to neratinib is with everolimus, a TORC1 inhibitor commonly used to treat other types of breast cancer. Based on these findings, clinicians were lead to a potential way to counter the neratinib resistance. A...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).